# OnCo record lung-map-s1400i (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lung-map-s1400i/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lung-map-s1400i", "NCT02785952" ;
  schema:name "Lung-MAP S1400I: nivolumab with or without ipilimumab"@en ;
  schema:alternateName "S1400I"@en, "SWOG S1400I"@en ;
  schema:description "The first phase 3 to run inside Lung-MAP asked whether adding a second immunotherapy drug, ipilimumab, to nivolumab helps people with squamous lung cancer. It did not: survival was no better and side effects were worse."@en ;
  schema:url <https://onco.cc/trials/lung-map-s1400i/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02785952>, <https://doi.org/10.1001/jamaoncol.2021.2209> ;
  onco:status "negative" ;
  onco:phase "3" ;
  schema:startDate "2015-12-29" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/swog/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/basket-umbrella-platform/> ;
  onco:trials <https://onco.cc/trials/lung-map/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lung-map-s1400i-jama-oncol-2021/> .